Aptose Biosciences Inc(APS-T)TSX
Today's Change
Real-Time Last Update
Pre Market Change
Pre Market Last Update
Volume
Day Low2.20
Day High2.20
Open:2.20
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Profile
Aptose Biosciences Inc is a clinical-stage biotechnology company. Its compound tuspetinib is a convenient once daily oral agent that potently targets SYK, mutated and wild-type forms of FLT3, mutated KIT, JAK1/2, and RSK2 kinases, while avoiding many typical toxicity concerns observed with other agents. The ongoing TUSCANY triplet Phase 1/2 study is designed to test various doses and schedules of TUS in combination with standard dosing of azacitidine and venetoclax in newly diagnosed patients with AML who are ineligible to receive induction chemotherapy. The group has reported data from the first three dose cohorts that demonstrated safety, CRs, and minimal residual disease (MRD) negativity across patients with diverse mutations.